Courtney Crawford, MD
Retina Specialist · Burleson, TXNPI 1265546170
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $233,925 of the $342,118 with a category attached, or 68.4%. 30 manufacturers reported payments, led by Baxter Healthcare at 45.0% of the total. Reporting peaked in 2023 at $166,126 and has fallen 78.5% since, to $35,744 in 2025. Among retina specialist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $1402.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$154K
- Apellis Pharmaceuticals, Inc.$46K
- Regeneron Healthcare Solutions, Inc.$37K
- Alcon$32K
- Genentech, Inc.$11K
- Ocular Therapeutix, Inc.$11K
- plus $51K from 24 others
Across 153 payments — averaging $5626.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$534K
- Alcon Research LLC$144K
- AbbVie$82K
- Amgen$53K
- Regeneron$40K
- Boehringer Ingelheim International GmbH$9K
- plus $600 from 1 others
What the payments were for
- Consulting fees$233,92568%
- Speaking & faculty fees$78,23323%
- Travel & lodging$22,8957%
- Food & beverage$6,5892%
- Education$4770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 24 | $154,080 |
| Apellis Pharmaceuticals, Inc. | 35 | $46,070 |
| Regeneron Healthcare Solutions, Inc. | 22 | $37,315 |
| Alcon | 37 | $31,726 |
| Genentech, Inc. | 9 | $11,141 |
| Ocular Therapeutix, Inc. | 10 | $10,990 |
| Dutch Ophthalmic, USA | 14 | $10,765 |
| AbbVie(2 entities) | 21 | $10,181 |
| Alcon Research LLC | 9 | $7,322 |
| Regeneron | 9 | $5,888 |
| Genentech USA, Inc. | 14 | $5,063 |
| Eyepoint US, Inc. | 7 | $3,524 |
| Mallinckrodt Enterprises LLC | 3 | $3,513 |
| Astellas Pharma US Inc | 8 | $2,606 |
| Oculus Surgical Inc. | 1 | $975 |
| Carl Zeiss Meditec USA, Inc. | 2 | $323 |
| Welch Allyn | 1 | $150 |
| Alimera Sciences, Inc. | 4 | $103 |
| Novartis | 2 | $79 |
| Biotissue Holdings Inc. | 2 | $71 |
| Coherus Oncology, Inc. | 1 | $42 |
| Sandoz | 1 | $26 |
| Harrow Eye, LLC | 1 | $24 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Biogen | 1 | $23 |
| Optos, Inc. | 1 | $23 |
| Dutch Ophthalmic Research Center (international) B.v. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $15 |
| Neurotech Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hillrom - RetinaVue 700 Imager$154,080
- Hillrom - RetinaVue Network$154,080
- Syfovre$44,376
- EYLEA HD$42,727
- Constellation$17,690
- VABYSMO$12,351
- EVA, combined machine$10,526
- NGENUITY$8,302
- TISSUEBLUE$8,276
- FINESSE SHARKSKIN$7,193
- ACTHAR$3,492
- EYP-1901$3,478
- OZURDEX$2,638
- Izervay$2,450
- Unity$2,128
- Lucentis$1,760
- Non-Covered Product$1,746
- AcrySof$980
- WaveLight EX500 Excimer Laser$980
- Luxor$980
How this compares
$342,118 in reported general payments places this provider in the 95th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 175 | $9,440 |
| MoxifloxacinMoxifloxacin Hcl | 124 | $3,420 |
| Brimonidine Tartrate | 153 | $2,841 |
| Latanoprost | 86 | $736 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $613 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $390 |
| ErythromycinErythromycin Base | 23 | $241 |
| Methylprednisolone | 27 | $208 |
| Timolol Maleate | 15 | $186 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 12 | $81 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Burleson
- Alexandria ChaulkBurleson$5K
- Jeremiah BrownSchertz$339K
- Victor GonzalezMcAllen$335K
- Judy KimDallas$256K
- Emmanuel ChangBellaire$254K
- Ting Fang SuarezBellaire$156K
- Hemang PandyaPlano$153K
- Margaret RunnerSouthlake$71K
- Moises ChicaSan Antonio$43K
- Garvin DavisHouston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.